Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Armond Schwartz

Gastroenterology Dallas, TX Medical Doctor

NPI 1245290071 CMS profile 101261

221 W. Colorado Blvd., Pavilion II Suite 630, Dallas, TX 75208

Open in the dashboard

General payments

$5,449

266 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$25,548

4 holdings reported · through program year 2025

Through program year 2025, Armond Schwartz of Dallas, TX is reported in the CMS Open Payments database as having received $5,449 across 266 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $25,548 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $842 46
2024 General $1,260 59
2023 General $872 54
2022 General $1,125 65
2021 General $565 28
2020 General $28 2
2019 General $757 12
2024 Ownership $12,055 1
2023 Ownership $12,055 1
2022 Ownership $757 1
2021 Ownership $682 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Armond Schwartz
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Armond Schwartz were reported at $842. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Armond Schwartz Gastroenterology median Middle half National median
2019 $757 $417 $126–$1,100 $163
2020 $28 $224 $74–$624 $114
2021 $565 $352 $106–$1,054 $132
2022 $1,125 $448 $129–$1,270 $149
2023 $872 $533 $150–$1,390 $160
2024 $1,260 $605 $160–$1,606 $164
2025 $842 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,848 94 payments
  2. Celgene Corporation $647 78 payments
  3. Shire North American Group Inc $500 1 payment
  4. Janssen Biotech, Inc. $479 21 payments
  5. E.R. Squibb & Sons, L.L.C. $338 3 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $195 7 payments
  7. Merck Sharp & Dohme Corporation $193 10 payments
  8. Celltrion USA Inc. $182 9 payments
  9. Pfizer Inc. $151 7 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $108 6 payments
  11. Other $807 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,895 260 payments
  2. Consulting Fee $500 1 payment
  3. Education $55 5 payments
Products named General payments · program years 2019–2025
  1. ZEPOSIA $963 78 payments
  2. RINVOQ $783 33 payments
  3. SKYRIZI $594 28 payments
  4. CREON $528 37 payments
  5. LINZESS $495 36 payments
  6. STELARA $474 17 payments
  7. TREMFYA $242 6 payments
  8. DIFICID $193 10 payments
  9. VEGZELMA $182 9 payments
  10. ENTYVIO $160 5 payments
  11. Other $1,731 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,851

Median for Gastroenterology: 569

Drug cost

$197,441

Median for Gastroenterology: $104,976

Branded share of claims

28.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xeljanz Tofacitinib Citrate Brand 13 $75,812
Zenpep Lipase/Protease/Amylase Brand 22 $55,082
Omeprazole Generic 609 $10,620
Linzess Linaclotide Brand 12 $10,436
Pentasa Mesalamine Brand 11 $7,538
Mesalamine Generic 26 $7,216
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 340 $6,775
Ursodiol Generic 25 $4,471
Cholestyramine Light Cholestyramine Brand 31 $2,917
Sucralfate Generic 109 $2,143

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$87,773

Medicare's payments for the services billed

Medicare patients

422

Average age 72

Services billed

998

259 women, 163 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Chronic kidney disease 38%
Diabetes 37%
Ischemic heart disease 30%
Depression 21%
Heart failure 20%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPOSIA
  • Celgene Corporation $142
  • E.R. Squibb & Sons, L.L.C. $116
$258 — —
RINVOQ
  • AbbVie, Inc. $227
$227 — —
STELARA
  • Janssen Biotech, Inc. $131
$131 — —
TREMFYA
  • Janssen Biotech, Inc. $108
$108 — —
SKYRIZI
  • AbbVie, Inc. $102
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record